当前位置:
X-MOL 学术
›
Oncol. Res. Treat.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cabozantinib plus Nivolumab: Neuer RCC-Erstlinienstandard?
Oncology Research and Treatment ( IF 2.4 ) Pub Date : 2021-05-28
Oncol Res Treat 2021;44:362–363
中文翻译:
卡博替尼加纳武单抗:Neuer RCC-Erstlinien 标准?
Oncol Res Treat 2021;44:362–363
更新日期:2021-05-28
Oncology Research and Treatment ( IF 2.4 ) Pub Date : 2021-05-28
Oncol Res Treat 2021;44:362–363
中文翻译:
卡博替尼加纳武单抗:Neuer RCC-Erstlinien 标准?
Oncol Res Treat 2021;44:362–363